<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20857" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Eccrine Carcinoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kaseb</surname>
            <given-names>Hatem</given-names>
          </name>
          <aff>Cleveland Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Babiker</surname>
            <given-names>Hani M.</given-names>
          </name>
          <aff>University of Arizona Cancer Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hatem Kaseb declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hani Babiker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20857.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Eccrine carcinoma (EC) is a rare carcinoma that originates from the eccrine sweat glands of the skin and accounts for less than 0.01% of diagnosed cutaneous malignancies. Sweat gland tumors have been traditionally subdivided into four large groups: Eccrine, apocrine, mixed origin (eccrine and apocrine), and other un-classifiable sweat gland tumors. Eccrine tumors are divided into benign and malignant. This activity reviews the evaluation, differential, and treatment of sweat gland tumors and highlights the role of the interprofessional team in treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the risk factors for sweat gland tumors.</p></list-item><list-item><p>Describe the presentation of a patient with a sweat gland tumor.</p></list-item><list-item><p>Summarize the treatment options for sweat gland tumors.</p></list-item><list-item><p>Explain the importance of improving care coordination amongst the interprofessional team to enhance the delivery of care for patients with sweat gland tumors.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20857&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20857">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20857.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Eccrine carcinoma (EC) is a rare carcinoma that originates from the eccrine sweat glands of the skin and accounts for less than 0.01% of diagnosed cutaneous malignancies.<xref ref-type="bibr" rid="article-20857.r1">[1]</xref> Sweat gland tumors have traditionally subdivided into four broad groups: eccrine, apocrine, mixed origin (eccrine and apocrine), and other unclassifiable sweat gland tumors. Eccrine tumors further divide into benign and malignant. Benign entities include poroma, hidradenoma, spiradenoma, cylindroma, syringometaplasia, syringoma, syringofibroadenoma, and chondroid syringoma. Malignant eccrine carcinoma entities include porocarcinoma, hidradenocarcinoma, malignant spiradenoma carcinoma, malignant cylindroma, syringoid eccrine carcinoma, microcystic adnexal carcinoma, mucinous carcinoma, adenoid cystic carcinoma, and ductal papillary adenocarcinoma. Other un-classifiable sweat gland tumors include eccrine ductal carcinoma, basaloid eccrine carcinoma, clear cell eccrine carcinoma, and non-specified sweat gland carcinomas.</p>
        <p>Malignant sweat gland tumors are heterogeneous neoplasms of different biological behavior.<xref ref-type="bibr" rid="article-20857.r2">[2]</xref> The principal characteristic of these tumors is that they are locally aggressive and show a high rate of recurrence. Separation of eccrine carcinoma has traditionally been according to their behavior into low grade and high grade malignant.<xref ref-type="bibr" rid="article-20857.r3">[3]</xref> Proper identification of eccrine carcinoma is sometimes challenging due to the morphological similarity to other common tumors and the lack of consistent immunohistochemical markers.&#x000a0;</p>
      </sec>
      <sec id="article-20857.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Research has not uncovered a clear etiology.</p>
      </sec>
      <sec id="article-20857.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Eccrine carcinoma is an extremely rare cutaneous malignancy that accounts for less than 0.01% of diagnosed cutaneous malignancies.<xref ref-type="bibr" rid="article-20857.r1">[1]</xref></p>
      </sec>
      <sec id="article-20857.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Sweat gland tumors divide into eccrine, apocrine, mixed origin (eccrine and apocrine), and other un-classifiable sweat gland tumors. In real practice, most sweat gland tumors have both eccrine and apocrine components. Some even show complexity such as showing other lines of differentiation, namely follicular and/or sebaceous.<xref ref-type="bibr" rid="article-20857.r4">[4]</xref> This differentiation is possibly due to the close embryological relationship between apocrine glands and pilosebaceous units. &#x000a0;Histopathologies closely associated with eccrine carcinoma include hidradenocarcinoma, spiradenocarcinoma, and porocarcinoma.<xref ref-type="bibr" rid="article-20857.r2">[2]</xref>&#x000a0;</p>
        <p>Some relatively important and common types of eccrine carcinoma include porocarcinomas, syringoid carcinoma, ductal carcinomas, adenoid cystic carcinomas, and mucinous carcinomas.<xref ref-type="bibr" rid="article-20857.r5">[5]</xref> Porocarcinomas are characteristically solid neoplastic lobular masses with cystic changes and necrosis. Two types of atypical cells are present in porocarcinomas: eosinophilic and clear cells. These tumor cells are usually positive for cytokeratin and PAS. Syringoid carcinoma shows a mix of tubules, keratinizing cystic structures, solid islands, cellular cords, and desmoplastic stroma, resembling syringomas to some extent. Ductal carcinomas characteristically demonstrate by the presence of tubular structures mixed with variable amounts of cellular cords. The degree of differentiation range from well to poorly differentiated. Tumor cells are positive for PAS, D-PAS and, cytokeratins.<xref ref-type="bibr" rid="article-20857.r6">[6]</xref> Adenoid cystic carcinomas are morphologically composed of basaloid and monomorphous cells; moderately atypical with hyperchromatic nuclei and inconspicuous cytoplasm. Tumor cells typically arrange in cribriform masses, islands, and tubular structures. Mucinous carcinomas are morphologically composed of cells, arranged in solid islands, cribriform masses, tubules, and small nests embedded in large mucin pools.<xref ref-type="bibr" rid="article-20857.r5">[5]</xref></p>
        <p>Immunohistochemistry and molecular genetics play only a minor role in the diagnosis of sweat gland tumors, however, can be useful in excluding other possible entities. One relevant entity to exclude is cutaneous metastases from visceral primary adenocarcinomas.<xref ref-type="bibr" rid="article-20857.r3">[3]</xref> When pathological complexity is evident, and the pathologist cannot fit the case to any established category, they should render a descriptive diagnosis of benign/malignant tumor with sweat gland differentiation.<xref ref-type="bibr" rid="article-20857.r7">[7]</xref></p>
      </sec>
      <sec id="article-20857.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>EC presents as a brown, bluish, erythematous nodule, papule, or ulcerative lesion. Lesions can present anywhere in the body. However, the lower extremities (35%), head and neck (24%), and upper extremities (14%) are common regions.<xref ref-type="bibr" rid="article-20857.r2">[2]</xref><xref ref-type="bibr" rid="article-20857.r8">[8]</xref></p>
      </sec>
      <sec id="article-20857.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The test of choice in the diagnosis of eccrine carcinoma is a skin biopsy. The biopsy will show infiltrative, moderately to poorly differentiated neoplasm in a nested to the trabecular pattern. Nuclei are relatively uniform with notably prominent nucleoli. The specific morphology depends on the distinct eccrine carcinoma entity. Relatively common types of eccrine carcinoma include porocarcinomas, syringoid carcinoma, ductal carcinomas, adenoid cystic carcinomas, and mucinous carcinomas.<xref ref-type="bibr" rid="article-20857.r5">[5]</xref> Immunohistochemistry (IHC) may be helpful in some cases; however, it is inconsistent. Markers that can support an EC diagnosis include carcinoembryonic antigen (CEA), epithelial membrane antigen (EMA), estrogen receptors (ER), progesterone receptors (PR), cytokeratin 7 (CK-7), and pancytokeratins.<xref ref-type="bibr" rid="article-20857.r9">[9]</xref><xref ref-type="bibr" rid="article-20857.r10">[10]</xref></p>
      </sec>
      <sec id="article-20857.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Wide surgical excision with the goal of clear margins is the treatment of choice of EC.<xref ref-type="bibr" rid="article-20857.r4">[4]</xref> Chemotherapy and radiation therapy have been used for metastatic lesions.<xref ref-type="bibr" rid="article-20857.r1">[1]</xref> Because EC is an infrequent entity, no randomized control trials exist that examine the management options.</p>
      </sec>
      <sec id="article-20857.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Basal cell carcinoma (BCC): BCC is the most common malignancy of skin and approximately constitutes up to 80% of all skin cancers. BCC occurs more commonly in the sun-exposed skin. The most common presentation of BCC is in the form of a papule or a nodule. Morphologically BCC appears as basaloid cells with scant cytoplasm and elongated hyperchromatic nuclei. Positive stains that aid in confirming the diagnosis include: BerEP4, 34betaE12, MNF 116, p53, BCL2, and p63. Negative stains include EMA, CEA, involucrin, and CK20.</p>
          </list-item>
          <list-item>
            <p>Squamous cell carcinoma (SCC): SCC is the second most malignancy of skin. SCC is graded based on the degree of differentiation and keratinization into well, moderately, and poorly differentiated. Common presentations of SCC include a thin plaque or erythematous scaly papule. Positive stains that aid in confirming the diagnosis include: 34betaE12, AE1/AE3, CK5/6, EMA, and p63. Negative stains include CAM5.2, BerEP4, S100, and SMA.</p>
          </list-item>
          <list-item>
            <p>Amelanotic melanoma: Amelanotic melanoma is a variant of melanoma that presents as white or reddish lesions. Similar to other common skin malignancies amelanotic melanoma is more common in sun-exposed skin. Similar to malignant melanoma, Amelanotic melanoma prognosis is determined by two important factors that include lesion thickness and lesion degree of invasion.</p>
          </list-item>
          <list-item>
            <p>Seborrheic keratosis: These are benign skin lesions affecting primarily adult patients. The lesion presents as a sharply demarcated pigmented greasy lesion that elevates above the surface of the skin. On microscopic examination, the lesion appears as an acanthotic proliferations of small cuboidal keratinocytes without any evidence of cytological atypia.</p>
          </list-item>
          <list-item>
            <p>Cutaneous lymphoma.</p>
          </list-item>
          <list-item>
            <p>Verruca vulgaris.</p>
          </list-item>
          <list-item>
            <p>Metastatic carcinoma: Skin metastases from breast, lung, or kidney carcinoma should be kept in the differential of eccrine carcinoma.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20857.s10" sec-type="Staging">
        <title>Staging</title>
        <p>Eccrine carcinoma pathologically stages (pTNM) as follows:</p>
        <p>Primary Tumor (pT)</p>
        <list list-type="bullet">
          <list-item>
            <p>pTX: Primary tumor not assessable</p>
          </list-item>
          <list-item>
            <p>pT0: No evidence of primary tumor</p>
          </list-item>
          <list-item>
            <p>pTis: Carcinoma in situ</p>
          </list-item>
          <list-item>
            <p>pT1: Tumor 2 cm or less in the largest dimension
<list list-type="bullet"><list-item><p>pT1a: Limited to the dermis or 2 mm or less in thickness</p></list-item><list-item><p>pT1b: Limited to the dermis and more than 2 mm in thickness, but not more than 6 mm in thickness</p></list-item><list-item><p>pT1c: Invading the subcutis and/or more than 6 mm in thickness</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>pT2: Tumor greater than 2 cm but not more than 5 cm in its greatest dimension
<list list-type="bullet"><list-item><p>pT2a: Limited to the dermis or 2 mm or less in thickness</p></list-item><list-item><p>pT2b: Limited to the dermis and more than 2 mm in thickness but not more than 6 mm in thickness</p></list-item><list-item><p>pT2c: Invading the subcutis and/or more than 6 mm in thickness</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>pT3: Tumor over 5 cm in its greatest dimension
<list list-type="bullet"><list-item><p>pT3a: Limited to the dermis or 2 mm or less in thickness</p></list-item><list-item><p>pT3b: Limited to the dermis and more than 2 mm in thickness, but not more than 6 mm in thickness</p></list-item><list-item><p>pT3c: Invading the subcutis and/or more than 6 mm in thickness</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>pT4: Tumor invades the deep extradermal tissue (e.g., cartilage, skeletal muscle, bone)
<list list-type="bullet"><list-item><p>pT4a: 6 mm or less in thickness</p></list-item><list-item><p>pT4b: More than 6 mm in thickness</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Regional Lymph Nodes (pN)</p>
        <list list-type="bullet">
          <list-item>
            <p>pNX: Regional lymph nodes not</p>
          </list-item>
          <list-item>
            <p>assessablepN0: No regional lymph node metastasis</p>
          </list-item>
          <list-item>
            <p>pN1: Regional lymph node metastasis</p>
          </list-item>
        </list>
        <p>Distant Metastasis (pM)</p>
        <list list-type="bullet">
          <list-item>
            <p>pMX: Presence of distant metastasis not</p>
          </list-item>
          <list-item>
            <p>assessablepM1: Distant metastasis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20857.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Metastatic disease shows a poor prognosis. The relative mortality rate is 80%, and the 10-year disease overall survival rate is 9%.<xref ref-type="bibr" rid="article-20857.r2">[2]</xref></p>
      </sec>
      <sec id="article-20857.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Eccrine carcinoma complications include metastases and/or adverse effects related to surgical intervention.</p>
      </sec>
      <sec id="article-20857.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should receive education regarding the prognosis and the possible adverse side effects of surgical intervention before beginning treatment.</p>
      </sec>
      <sec id="article-20857.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Eccrine carcinoma is an extremely rare cutaneous malignancy. The prognosis is overall favorable in localized early lesions, however an unfavorable prognosis in metastatic lesions.<xref ref-type="bibr" rid="article-20857.r1">[1]</xref> Eccrine carcinoma needs an interprofessional management approach with a medical oncologist, surgeon, dermatologist, dermatopathologist, pharmacist, and oncology nurse all playing a role in the management of the condition and working collaboratively to bring about optimal patient treatment and outcomes. [Level 5]</p>
      </sec>
      <sec id="article-20857.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20857&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20857">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/eccrine-carcinoma-cancer-of-the-sweat-glands/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20857">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20857/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20857">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20857.s16">
        <title>References</title>
        <ref id="article-20857.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sidiropoulos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sade</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Al-Habeeb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghazarian</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Syringoid eccrine carcinoma: a clinicopathological and immunohistochemical study of four cases.</article-title>
            <source>J Clin Pathol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>64</volume>
            <issue>9</issue>
            <fpage>788</fpage>
            <page-range>788-92</page-range>
            <pub-id pub-id-type="pmid">21642659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20857.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Babiker</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Kovoor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eldersveld</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Elquza</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma.</article-title>
            <source>Case Rep Oncol Med</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>7127048</fpage>
            <pub-id pub-id-type="pmid">29686913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20857.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Horst</surname>
                <given-names>MPJ</given-names>
              </name>
              <name>
                <surname>Brenn</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Update on Malignant Sweat Gland Tumors.</article-title>
            <source>Surg Pathol Clin</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>383</fpage>
            <page-range>383-397</page-range>
            <pub-id pub-id-type="pmid">28477887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20857.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moy</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Rivkin</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Zitelli</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Syringoid eccrine carcinoma.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1991</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5 Pt 2</issue>
            <fpage>857</fpage>
            <page-range>857-60</page-range>
            <pub-id pub-id-type="pmid">2050853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20857.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Urso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bondi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paglierani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salvadori</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anichini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giannini</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Carcinomas of sweat glands: report of 60 cases.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>125</volume>
            <issue>4</issue>
            <fpage>498</fpage>
            <page-range>498-505</page-range>
            <pub-id pub-id-type="pmid">11260623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20857.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abedi</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Salama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alowami</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Syringoid eccrine carcinoma.</article-title>
            <source>Cutis</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>96</volume>
            <issue>3</issue>
            <fpage>162</fpage>
            <page-range>162,191-2</page-range>
            <pub-id pub-id-type="pmid">26562272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20857.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cardoso</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Calonje</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Malignant sweat gland tumours: an update.</article-title>
            <source>Histopathology</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>67</volume>
            <issue>5</issue>
            <fpage>589</fpage>
            <page-range>589-606</page-range>
            <pub-id pub-id-type="pmid">26114606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20857.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Idrissi Serhrouchni</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harmouch</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chbani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>El Fatemi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sekal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hammas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Soughi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benchat</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Amarti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Eccrine carcinoma : a rare cutaneous neoplasm.</article-title>
            <source>Diagn Pathol</source>
            <year>2013</year>
            <month>Feb</month>
            <day>04</day>
            <volume>8</volume>
            <fpage>15</fpage>
            <pub-id pub-id-type="pmid">23379908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20857.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swanson</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Cherwitz</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Wick</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Eccrine sweat gland carcinoma: an histologic and immunohistochemical study of 32 cases.</article-title>
            <source>J Cutan Pathol</source>
            <year>1987</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>65</fpage>
            <page-range>65-86</page-range>
            <pub-id pub-id-type="pmid">2439558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20857.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohnishi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Egi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takizawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Syringoid eccrine carcinoma: report of a case with immunohistochemical analysis of cytokeratin expression.</article-title>
            <source>Am J Dermatopathol</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>409</fpage>
            <page-range>409-13</page-range>
            <pub-id pub-id-type="pmid">12357203</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
